Glucose transporter 4 mRNA expression in subcutaneous adipose tissue of women with PCOS remains unchanged despite metformin withdrawal: is there a cellular metabolic treatment legacy effect?

Jensterle, Mojca; Kravos, Nika Aleksandra; Dolžan, Vita; Goričar, Katja; Herman, Rok; Rizzo, Manfredi

doi:10.1007/s12020-021-02934-4

Cited by 3 publications

(1 citation statement)

References 64 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, at the time of recruitment, 12 out of 20 participants were already taking metformin, and the study had a six-week run-in period when medication was discontinued. The duration of this run-in period is important in light of a recent study that concluded that six months after metformin withdrawal, GLUT4 mRNA expression in subcutaneous adipose tissue of PCOS patients remained stable [105]. Another study in patients with T2DM showed that metformin treatment for 10 weeks significantly increased AMPK activity in skeletal muscle, and the observed effect was associated with phosphorylation of AMPK at Thr 172 and resulted in enhanced peripheral glucose uptake [92].…”

Section: Ampk Activationmentioning

confidence: 99%

Metformin and Insulin Resistance: A Review of the Underlying Mechanisms behind Changes in GLUT4-Mediated Glucose Transport

Herman

Kravos

Jensterle

et al. 2022

IJMS

Self Cite

101

View full text Add to dashboard Cite

Metformin is the most commonly used treatment to increase insulin sensitivity in insulin-resistant (IR) conditions such as diabetes, prediabetes, polycystic ovary syndrome, and obesity. There is a well-documented correlation between glucose transporter 4 (GLUT4) expression and the level of IR. Therefore, the observed increase in peripheral glucose utilization after metformin treatment most likely comes from the induction of GLUT4 expression and its increased translocation to the plasma membrane. However, the mechanisms behind this effect and the critical metformin targets are still largely undefined. The present review explores the evidence for the crucial role of changes in the expression and activation of insulin signaling pathway mediators, AMPK, several GLUT4 translocation mediators, and the effect of posttranscriptional modifications based on previously published preclinical and clinical models of metformin’s mode of action in animal and human studies. Our aim is to provide a comprehensive review of the studies in this field in order to shed some light on the complex interactions between metformin action, GLUT4 expression, GLUT4 translocation, and the observed increase in peripheral insulin sensitivity.

show abstract

Section: Ampk Activationmentioning

confidence: 99%

Metformin and Insulin Resistance: A Review of the Underlying Mechanisms behind Changes in GLUT4-Mediated Glucose Transport

Herman

Kravos

Jensterle

et al. 2022

IJMS

Self Cite

101

View full text Add to dashboard Cite

show abstract

Polycystic ovary syndrome and adipose tissue

Lemaître

Christin-Maître

Kerlan

2023

Annales d'Endocrinologie

View full text Add to dashboard Cite

Signaling pathways and targeted therapeutic strategies for polycystic ovary syndrome

Wang,

2023

Front. Endocrinol.

View full text Add to dashboard Cite

Polycystic ovary syndrome (PCOS) is the most common endocrine disorder among women of reproductive age. Although promising strides have been made in the field of PCOS over the past decades, the distinct etiologies of this syndrome are not fully elucidated. Prenatal factors, genetic variation, epigenetic mechanisms, unhealthy lifestyles, and environmental toxins all contribute to the development of this intricate and highly heterogeneous metabolic, endocrine, reproductive, and psychological disorder. Moreover, interactions between androgen excess, insulin resistance, disruption to the hypothalamic–pituitary–ovary (HPO) axis, and obesity only make for a more complex picture. In this review, we investigate and summarize the related molecular mechanisms underlying PCOS pathogenesis from the perspective of the level of signaling pathways, including PI3K/Akt, TGF-β/Smads, Wnt/β-catenin, and Hippo/YAP. Additionally, this review provides an overview of prospective therapies, such as exosome therapy, gene therapy, and drugs based on traditional Chinese medicine (TCM) and natural compounds. By targeting these aberrant pathways, these interventions primarily alleviate inflammation, insulin resistance, androgen excess, and ovarian fibrosis, which are typical symptoms of PCOS. Overall, we hope that this paper will pave the way for better understanding and management of PCOS in the future.

show abstract

Glucose transporter 4 mRNA expression in subcutaneous adipose tissue of women with PCOS remains unchanged despite metformin withdrawal: is there a cellular metabolic treatment legacy effect?

Cited by 3 publications

References 64 publications

Metformin and Insulin Resistance: A Review of the Underlying Mechanisms behind Changes in GLUT4-Mediated Glucose Transport

Metformin and Insulin Resistance: A Review of the Underlying Mechanisms behind Changes in GLUT4-Mediated Glucose Transport

Polycystic ovary syndrome and adipose tissue

Signaling pathways and targeted therapeutic strategies for polycystic ovary syndrome

Contact Info

Product

Resources

About